Cantex and Headlamp Partner to Advance Azeliragon for MS Depression and Fatigue

May 14, 2026
Cantex Pharmaceuticals and Headlamp Health have announced a partnership to use Headlamp's Lumos AI platform to accelerate the development of azeliragon for treating severe depression and fatigue in multiple sclerosis patients.

Cantex Pharmaceuticals and Headlamp Health announced in a press release a collaboration to apply Headlamp's Lumos AI platform to the clinical development of azeliragon for severe depression and fatigue in patients with multiple sclerosis.

Headlamp's Lumos AI is a neuro symbolic, multi agent platform designed for neuropsychiatric drug development. It integrates biological, behavioral, biomarker, and clinical data into a unified intelligence layer, helping teams identify responder and non responder subtypes earlier and refine trial design.

Under the agreement, Headlamp Health will deploy Lumos AI to analyze data across azeliragon's development program. Azeliragon is an oral, blood brain barrier penetrant RAGE inhibitor in clinical development, targeting neuroinflammatory processes linked to depression and fatigue in multiple sclerosis patients.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Enterprise AI Brief, Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Enterprise AI Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Enterprise

05/14
Actabl Receives U.S. Patent for Hotel Data Normalization System
05/14
Digital Turbine Integrates Databricks Platform to Advance Mobile AI
05/14
SoftBank Robotics America Extends Partnership with Direct Supply for Senior Living Facilities
05/14
CockroachDB Now Available on IBM Cloud and IBM Power Systems
05/14
Harness Report Finds AI Productivity Gains Outpacing Developer Measurement Systems

More from: Life Sciences

05/14
Global Healthcare Exchange Launches AI Orchestration Platform for Healthcare Supply Chains
05/14
Natus Medical Forms Global EEG Advisory Board to Guide AI and Clinical Strategy
05/14
Corti Launches Startup Program to Support Healthcare AI Builders
05/13
SOPHiA GENETICS and Synnovis Partner to Expand Blood-Based Cancer Testing in the UK
05/13
Cellular Intelligence Acquires Novo Nordisk Parkinson's Cell Therapy Program

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Market report

Superagency in the Workplace: Empowering People to Unlock AI’s Full Potential

This report explores the transformative potential of artificial intelligence in the workplace, emphasizing the readiness of employees versus the slower adaptation of leadership. It highlights the significant productivity growth potential AI offers, akin to historical technological shifts, and discusses the barriers to achieving AI maturity within organizations. The report also examines the role of leadership in steering companies towards effective AI integration and the need for strategic investments to harness AI's full capabilities.

Read more

You May Also Like